Download PDF

Pneumocystis Infections¶

Chapter 227 | Part 5: Infectious Diseases · Part 5 – Infectious Diseases: Fungal · Part 5 – Infectious Diseases: Fungal · Chapter 227

Key Clinical Points¶

Pneumocystis jirovecii is an opportunistic fungal pathogen causing pneumonia primarily in immunocompromised hosts (HIV/AIDS, transplant, high-dose steroids).
Diagnosis requires demonstration of organisms via bronchoalveolar lavage (BAL) fluid (100% sensitive/specific), lung biopsy, or induced sputum (55–90% sensitivity).
First-line treatment is TMP-SMX: 14 days for non-HIV mild disease; 21 days for other cases.
Glucocorticoids are indicated for moderate/severe PCP (PaO2 <70 mmHg or A-a gradient ≥35 mmHg).
A normal chest CT effectively rules out Pneumocystis pneumonia (PCP).
CD4+ T-cell count <200/μL is a major risk factor in HIV, but not a reliable predictor in non-HIV populations.
Common radiographic findings include diffuse bilateral interstitial infiltrates and ground-glass opacities on CT.
TMP-SMX hypersensitivity is common; alternatives include Atovaquone, Clindamycin-Primaquine, or Pentamidine.
Untreated PCP is invariably fatal; mortality risk increases with age, severity of immunosuppression, and need for ventilation.
Prophylaxis is standard for at-risk patients, primarily using TMP-SMX.

1. DEFINITION & OVERVIEW¶

Pneumocystis is an opportunistic fungal pathogen causing pneumonia primarily in immunocompromised hosts.

Definition (Harrison's 22e): Pneumocystis is an opportunistic pathogen that is an important cause of pneumonia in immunocompromised hosts, particularly those with HIV infection, organ transplants, or hematologic malignancies and those receiving high-dose glucocorticoids or certain immunosuppressive monoclonal antibodies.

• Classification: ◦ Formerly Pneumocystis carinii; renamed Pneumocystis jirovecii for the human-specific species. ◦ Classified as a fungus (previously thought to be protozoan).

• Transmission: ◦ Respiratory route. ◦ Humans are only infected by P. jirovecii from other humans. ◦ Most humans exposed early in life.

1.1 Organism Biology¶

• Life Cycle: Includes trophic form, cyst, and precyst. • Host Range: ◦ Immunocompetent animals can serve as reservoirs for respiratory transmission. ◦ Human-specific: Humans only infected by P. jirovecii (not from rodent/rabbit species). • Clinical Significance: ◦ Subclinical infection documented in immunocompetent individuals. ◦ Primary infection or reinfection can cause PCP, not just reactivation. ◦ Nosocomial outbreaks occur among immunosuppressed patients.

2. EPIDEMIOLOGY¶

• History: First recognized in 1950s; linked to early AIDS cases in 1981. • Trends: Incidence peaked during AIDS epidemic; now more common in non-HIV-related immunosuppression due to improved diagnostics and prophylaxis.

2.1 Risk Factors¶

• HIV Infection: CD4+ <200/μL. • Transplantation: Solid-organ or hematopoietic stem cell transplantation. • Medications: ◦ High-dose glucocorticoids. ◦ Monoclonal antibodies (rituximab, alemtuzumab). ◦ Fludarabine, temozolomide, temsirolimus. • Other: ◦ Congenital immunodeficiencies. ◦ Neutropenia.

3. ETIOLOGY & PATHOPHYSIOLOGY¶

• Host Factors: ◦ HIV: 80% of cases occur at CD4+ <200/μL. ◦ Non-HIV: CD4+ count is less predictive; 200/μL does not provide protection. ◦ Duration of immunosuppression determines susceptibility period.

• Lung Pathology: ◦ Unique tropism for lung. ◦ Proliferation causes mononuclear response, alveolar filling with proteinaceous material, and surfactant abnormalities. ◦ Histopathology: Foamy exudates, interstitial edema/fibrosis. ◦ Identification: Silver/Giemsa/immunofluorescent stains.

3.1 Lung Pathology¶

• Pathology: ◦ Foamy exudates (pathognomonic). ◦ Interstitial edema and fibrosis. ◦ Identification: Silver/Giemsa/immunofluorescent stains identify organisms.

4. CLINICAL FEATURES¶

• Presentation: Acute/subacute pneumonia with dyspnea progressing to fever, cough, and hypoxemia. • Extrapulmonary: Rare (lymph nodes, spleen, liver); occasionally skin, retina, or brain.

• Clinical Course: ◦ HIV patients: May have indolent course and initially normal chest X-ray. ◦ Non-HIV patients: Often present with acute disease progressing to respiratory failure.

4.1 Physical Examination & Oxygenation¶

• Oxygenation: ◦ Decreased oxygen saturation at rest/exertion. ◦ Progresses to severe hypoxemia without treatment. • Auscultation: ◦ Initially normal chest exam; later develops diffuse rales or consolidation.

4.2 Radiographic Findings¶

• Chest X-ray (CXR): ◦ Initial CXR may be normal with mild symptoms. ◦ Classic: Diffuse bilateral interstitial infiltrates (perihilar, symmetric).

• Computed Tomography (CT): ◦ Shows ground-glass opacities (GGO) in all cases before CXR changes. ◦ Critical Rule: Normal CT essentially rules out PCP.

• Other Findings: ◦ Pneumatoceles/pneumothoraces common in HIV patients. ◦ Atypical: Asymmetric patterns, upper lobe infiltrates, nodules, effusions.

5. DIFFERENTIAL DIAGNOSIS¶

• Infiltrate Mimics: Other causes of diffuse bilateral interstitial infiltrates. • Concurrent Processes: Rule out concurrent infectious/neoplastic processes with extrapulmonary manifestations. • Non-infectious: Congestive heart failure, pulmonary emboli, drug toxicity, neoplasm.

6. INVESTIGATIONS & DIAGNOSIS¶

BAL Fluid Analysis:
Examination for organisms: 100% sensitive/specific.
H&E stain: Identifies pathognomonic foamy exudates and mononuclear infiltrate.
Silver/Giemsa/immunofluorescent stains: Required for specific organism identification.
Induced Sputum:
Sensitivity 55–90% (dependent on provider experience).
PCR Testing:
Highly sensitive; however, cannot distinguish colonization from infection.
Note: Negative results are more useful for ruling out PCP.
Serum Biomarkers:
(1→3)-β-d-glucan: Frequently elevated but not specific/sensitive.
Imaging Rule-out:
Normal chest CT → rules out PCP.

6.1 Diagnostic Criteria & Thresholds¶

• BAL Organisms: 100% sensitive/specific. • H&E Stain: Pathognomonic appearance (foamy exudates, mononuclear infiltrate). • Sputum Sensitivity: 55–90%. • Rule-out: Normal chest CT.

7. MANAGEMENT & TREATMENT¶

Initial Treatment (TMP-SMX):
First-line agent: Trimethoprim-Sulfamethoxazole (TMP-SMX).
Route: IV or PO.
Duration: 14 days for non-HIV mild disease; 21 days for all other cases.
Adjunctive Therapy (Glucocorticoids):
Indicated for moderate/severe disease.
Criteria: PaO2 <70 mmHg OR A-a gradient ≥35 mmHg.
Standard of care for HIV-associated moderate/severe PCP.
Alternative Agents (if TMP-SMX fails or is contraindicated):
Atovaquone.
Clindamycin + Primaquine.
Pentamidine.
HIV Specific Management:
ART initiation: Within 2 weeks of starting PCP treatment (consider IRIS risk).

7.1 Pharmacologic Therapy¶

• First-Line Agent: TMP-SMX - Dose: TMP 5 mg/kg + SMX 25 mg/kg q6–8h PO or IV (e.g., 2 double-strength tablets tid or qid). - Adverse Effects: Fever, rash, cytopenias, hepatitis, hyperkalemia.

• Alternative Agents: - Atovaquone: 750 mg bid PO; Side effects: Rash, fever, hepatitis. - Clindamycin + Primaquine: - Clindamycin: 300–450 mg q6h PO or 600 mg q6–8h IV. - Primaquine: 15–30 mg qd PO. - Risks: Hemolysis (G6PD deficiency), methemoglobinemia, neutropenia, rash. - Pentamidine: 3–4 mg/kg qd IV; Risks: Hypotension, azotemia, torsades de pointes.

• Adjunctive Agent: Prednisone or methylprednisolone - Dosing Regimens: - 40 mg bid ×5d, - 40 mg qd ×5d, - 20 mg qd ×11d. - Route: PO or IV. - Adverse Effects: Peptic ulcer, hyperglycemia, mood changes, hypertension.

7.2 Treatment Failure & Switching¶

Evaluation Period: Reevaluate after 3–4 days of no improvement.
Differential Diagnosis Check: Evaluate for concurrent infections (e.g., bacterial) or noninfectious causes (CHF, PE, drug toxicity).
Treatment Modification:
If TMP-SMX fails: Switch to Pentamidine or Clindamycin-Primaquine.
If not already on regimen: Add glucocorticoids.

8. COMPLICATIONS & PROGNOSIS¶

• Prognosis: Untreated PCP is invariably fatal.

• Mortality Risk Factors: - Age. - Degree of immunosuppression. - Preexisting lung disease. - Requirement for mechanical ventilation. - Development of pneumothorax.

8.1 Mortality Risk Factors¶

• Risk Factors: Age, severity of immunosuppression, preexisting lung disease, mechanical ventilation requirement, pneumothorax development.

9. SPECIAL CONSIDERATIONS¶

• Non-HIV Patients: CD4+ >200/μL does not provide protection. • Prophylaxis Strategy: - Most effective prevention: Eliminate cause of immunosuppression (e.g., ART for HIV). - Chemoprophylaxis recommended during period of susceptibility.

9.1 Prophylaxis¶

• First-Line: TMP-SMX 1 tablet (double- or single-strength) qd PO. - Note: High hypersensitivity risk; rechallenge for non-life-threatening reactions.

• Alternative Options: - Dapsone + Pyrimethamine + Leucovorin: - Option 1: Dapsone 50 mg bid or 100 mg qd; Pyrimethamine 50 mg weekly; Leucovorin 25 mg weekly. - Option 2: Dapsone 50 mg qd; Pyrimethamine 75 mg weekly; Leucovorin 25 mg weekly. - Note: Leucovorin ameliorates cytopenias from pyrimethamine. - Pentamidine Aerosol: 300 mg monthly via Respirgard II nebulizer (may cause bronchospasm; less effective than TMP-SMX/dapsone). - Atovaquone: 1500 mg qd PO (requires fatty meal). - Echinocandins: Uncertain role; not monotherapy.

10. KEY PEARLS & HIGH-YIELD POINTS¶

• Imaging: Normal chest CT rules out PCP. • HIV Status: CD4+ >200/μL is rarely associated with PCP in HIV patients, but does not protect non-HIV patients. • Laboratory Markers: - Normal LDH does not rule out PCP; elevated LDH is not specific. - Serum (1→3)-β-d-glucan: Frequently elevated but not specific/sensitive. • Microscopy: BAL fluid organisms are 100% sensitive/specific. • PCR: Not standardized; negative results are more useful for ruling out PCP. • Steroids: Glucocorticoids are standard of care for HIV-associated moderate/severe PCP.

Reference Tables¶

TABLE 227-1 Treatment of Pneumocystis Pneumonia a DRUG(S) First-Choice Agent TMP-SMX¶

Harrison's 22e, p.1734

DRUG(S)	DOSE, ROUTE	ADVERSE EFFECTS
First-Choice Agent
TMP-SMX	TMP (5 mg/kg) plus SMX (25 mg/kg) q6–8h PO or IV (i.e., 2 double-strength tablets tid or qid)	Fever, rash, cytopenias, hepatitis, hyperkalemia
Alternative Agents
	750 mg bid PO
Clindamycin plus Primaquine	300–450 mg q6h PO or 600 mg q6–8h IV 15–30 mg qd PO	Hemolysis (G6PD deficiency), methemoglobinemia, neutropenia, rash
	3–4 mg/kg qd IV
Adjunctive Agent
Prednisone or methylprednisolone	40 mg bid × 5 d, 40 mg qd × 5 d, 20 mg qd × 11 d; PO or IV	Peptic ulcer disease, hyperglycemia, mood alteration, hypertension

TABLE 227-2 Prophylaxis of Pneumocystis Pneumonia DRUG(S) First-Choice Agent TMP-SMX¶

Harrison's 22e, p.1734

DRUG(S)	DOSE, ROUTE	COMMENTS
First-Choice Agent
TMP-SMX	1 tablet (double- or single-strength) qd PO	Incidence of hypersensitivity is high. Rechallenge for non-life- threatening hypersensitivity; consider dose-escalation protocol.
Alternative Agents
	50 mg bid or 100 mg qd PO
Dapsone plus Pyrimethamine plus Leucovorin	50 mg qd PO 50 mg weekly PO 25 mg weekly PO	Leucovorin ameliorates cytopenias due to pyrimethamine.
	200 mg weekly PO 75 mg weekly PO 25 mg weekly PO
Pentamidine	300 mg monthly via Respirgard II nebulizer	Aerosol may cause bronchospasm. Pentamidine is probably less effective than TMP-SMX or dapsone regimens.
	1500 mg qd PO